- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001538
Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
18 to 60 years of age, HIV-1 negative by HIV-1 ELISA, HIV PCR and Western Blot analysis.
Subjects in good health with no evidence of underlying disease based on history, physical exam and laboratory analysis.
Must have normal organ function as characterized by the following:
Hematopoietic: absolute granulocyte count of at least 1500/mm(3); platelet count of at least 150, 000/mm(3); hematocrit within normal range.
Renal: BUN less than 23 mg/dl; creatine less than 1.6 mg/dl.
Hepatic: serum total bilirubin less than 1.5 mg%.
Metabolic: ALT less than or equal to 1.5 x upper limit of normal range; serum calcium within normal range; serum lactate within normal range; total serum CPK within normal range.
Endocrine: serum glucose -- within normal range.
Immunologic: CD4 count greater than or equal to 500 cells/mm(3); total serum immunoglobulin (IgM, IgG and IgA) levels within normal ranges.
No other clinically significant laboratory abnormalities.
All subjects must understand the basis of transmission of HIV and other common sexual and blood borne infections and agree to practice abstinence or clinically accepted methods of prevention, including barrier protection during intercourse for the duration of the study.
Female subjects of child bearing potential must have a negative pregnancy test.
Must be available for active follow-up.
Able to give informed consent by signing the Institutional Review Board (IRB)-approved consent form(s).
Must not have previous immunization with any experimental vaccine directed against HIV or receipt of any experimental agent within 30 days prior to enrollment.
Must not receive any blood product or immunoglobulin within 6 months prior to enrollment.
Must not be exposed to potentially infective HIV fluids within the prior 6 months or tested positive for HIV at any time.
No history of any prior disease or therapy which would affect immune function including:
Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
Radiation therapy or cytotoxic/cancer chemotherapy;
immunodeficiency or auto-immune disease;
Acute infection or a recent (within 6 months) history of chronic infection.
Female subjects must not be nursing a child.
Must not be taking any medication which may affect immune function, with the following exceptions: subjects may be taking low doses of nonprescription strength NSAIDS (e.g. ibuprofen or aspirin) or acetaminophen.
No known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or of any serious adverse reactions to vaccines.
No evidence of active drug or alcohol abuse or uncontrolled (unstable) psychiatric disorders which would interfere with study participation.
Must not be engaging in HIV-related high-risk behavior such as unprotected sex, sex with multiple partners, or intravenous drug use.
No evidence of infection with HBV, HIV-1, HCV or HTLV-1 using standard testing procedures.
Must not have any positive result for anti-DNA antibodies as measured by standard testing procedures (anti-DNA antibody and anti-nuclear antibody (ANA) assays. This study does permit enrollment of volunteers with a low positive ANA (less than or equal to 1:160) titers, if there is no clinical evidence of underlying disorders that are associated with a positive ANA, if no first degree relative has an autoimmune disease, and if anti-DNA and ENA are negative.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Publications and helpful links
General Publications
- Kovacs JA, Vasudevachari MB, Easter M, Davey RT, Falloon J, Polis MA, Metcalf JA, Salzman N, Baseler M, Smith GE, et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest. 1993 Aug;92(2):919-28. doi: 10.1172/JCI116667.
- Wang B, Boyer J, Srikantan V, Ugen K, Gilbert L, Phan C, Dang K, Merva M, Agadjanyan MG, Newman M, et al. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology. 1995 Aug 1;211(1):102-12. doi: 10.1006/viro.1995.1383.
- Abrignani S, Montagna D, Jeannet M, Wintsch J, Haigwood NL, Shuster JR, Steimer KS, Cruchaud A, Staehelin T. Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6136-40. doi: 10.1073/pnas.87.16.6136.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- 960050
- 96-I-0050
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acquired Immunodeficiency Syndrome
-
VA Eastern Colorado Health Care SystemPublic Health Grant Program, Veterans Health Administration Office of Public...CompletedHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) | Self-Directed ViolenceUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus | Acquired Immune Deficiency Syndrome Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus | Human Immunodeficiency VirusesUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH); Ministry of Health and Social Welfare...CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)Tanzania
-
Janssen-Cilag International NVCompletedHIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS VirusUnited Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
-
Emory UniversityGrady Health SystemCompleted
-
Columbia UniversityNational Institute of Nursing Research (NINR)CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)United States
-
St. Jude Children's Research HospitalCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immunodeficiency Syndrome (AIDS)United States
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Columbia UniversityNational Institute of Mental Health (NIMH)CompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)Ethiopia
-
Columbia UniversityCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)Lesotho
Clinical Trials on APL 400-003
-
Wyeth-Lederle VaccinesCompleted
-
Wyeth-Lederle VaccinesCompletedHIV Infections | HIV SeronegativityUnited States
-
ApollonCompleted
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisNot yet recruiting
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Not yet recruiting
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
-
University of North Carolina, Chapel HillNaturex SACompleted
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina